Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry

BACKGROUND: Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study evaluated the real-world impact of ETI on lung function, nutritional status, pulmonary exacerbation frequency, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutharsan, Sivagurunathan, Dillenhoefer, Stefanie, Welsner, Matthias, Stehling, Florian, Brinkmann, Folke, Burkhart, Manuel, Ellemunter, Helmut, Dittrich, Anna-Maria, Smaczny, Christina, Eickmeier, Olaf, Kappler, Matthias, Schwarz, Carsten, Sieber, Sarah, Naehrig, Susanne, Naehrlich, Lutz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405057/
https://www.ncbi.nlm.nih.gov/pubmed/37554663
http://dx.doi.org/10.1016/j.lanepe.2023.100690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405057/
https://www.ncbi.nlm.nih.gov/pubmed/37554663
http://dx.doi.org/10.1016/j.lanepe.2023.100690

Ejemplares similares